Cargando…

Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response

PURPOSE: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. METHODS: We retrospectively reviewed our database and enrolled patients with MPM who received...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahouma, Mohamed, Aziz, Hala, Ghaly, Galal, Kamel, Mohamed, Loai, Iman, Mohamed, Abdelrahman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697462/
https://www.ncbi.nlm.nih.gov/pubmed/28843224
http://dx.doi.org/10.22034/APJCP.2017.18.8.2073
_version_ 1783280627544489984
author Rahouma, Mohamed
Aziz, Hala
Ghaly, Galal
Kamel, Mohamed
Loai, Iman
Mohamed, Abdelrahman
author_facet Rahouma, Mohamed
Aziz, Hala
Ghaly, Galal
Kamel, Mohamed
Loai, Iman
Mohamed, Abdelrahman
author_sort Rahouma, Mohamed
collection PubMed
description PURPOSE: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. METHODS: We retrospectively reviewed our database and enrolled patients with MPM who received platinum containing chemotherapy (2012-2014). Clinico-pathological and laboratory data were retrieved and Cox and logistic regression multivariate analyses (MVA) were respectively used to identify predictors of survival and response to chemotherapy. Comparison of good vs poor performance status (PS≥II) was accomplished using the Chi (X2) test. Kaplan–Meier survival curves were also obtained and propensity-score matching was performed for survival comparison. RESULTS: Among 114 patients listed during the study period, 82 had good PS=0-I (median age 45years, 43 men, 30 smokers, median weight=77Kg, pretreatment haemoglobin (Hb) level=12g/dL, platelet count=372,000/μL, leukocytes=9,700/μL, neutrophils=6,100/μL, lymphocytes=1,890/μL and neutrophil/lymphocyte ratio (NLR)=3.60). Some 65 had asbestosis, 23 had chronic disease, 55 (67.1%) were responders to platinum containing first line chemotherapy. A total of 49 (59.8%) had epithelial MPM. Median-OS and PFS in good PS cases were 17 and 9 months, respectively, as compared to 16 and 8 months for the poor PS group. After matching, better OS was observed among good PS vs poor PS patients (p=0.024) but there was no PFS difference (p=0.176). Significant decrease in PFS was observed among those with advanced nodal N disease (median PFS in N0 and N+ was 10 and 5 months, respectively), non-responders (p=0.012), NLR (p=0.026) and those with an epithelial pathology (p=0.062). MVA demonstrated that advanced (N) status (p=0.015), being a non-responder (p<0.001), NLR (p=0.015) and smoking (p=0.07) adversely affected the prognosis. The only predictor of response was absence of metastasis (M0; p=0.04). CONCLUSIONS: In addition to previously recognized factors, like nodal status, response, smoking and NLR, better median survival was evident in our patients with a good PS. Early detection before development of metastasis warrants greater focus to allow better responses to be obtained.
format Online
Article
Text
id pubmed-5697462
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-56974622017-12-01 Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response Rahouma, Mohamed Aziz, Hala Ghaly, Galal Kamel, Mohamed Loai, Iman Mohamed, Abdelrahman Asian Pac J Cancer Prev Research Article PURPOSE: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. METHODS: We retrospectively reviewed our database and enrolled patients with MPM who received platinum containing chemotherapy (2012-2014). Clinico-pathological and laboratory data were retrieved and Cox and logistic regression multivariate analyses (MVA) were respectively used to identify predictors of survival and response to chemotherapy. Comparison of good vs poor performance status (PS≥II) was accomplished using the Chi (X2) test. Kaplan–Meier survival curves were also obtained and propensity-score matching was performed for survival comparison. RESULTS: Among 114 patients listed during the study period, 82 had good PS=0-I (median age 45years, 43 men, 30 smokers, median weight=77Kg, pretreatment haemoglobin (Hb) level=12g/dL, platelet count=372,000/μL, leukocytes=9,700/μL, neutrophils=6,100/μL, lymphocytes=1,890/μL and neutrophil/lymphocyte ratio (NLR)=3.60). Some 65 had asbestosis, 23 had chronic disease, 55 (67.1%) were responders to platinum containing first line chemotherapy. A total of 49 (59.8%) had epithelial MPM. Median-OS and PFS in good PS cases were 17 and 9 months, respectively, as compared to 16 and 8 months for the poor PS group. After matching, better OS was observed among good PS vs poor PS patients (p=0.024) but there was no PFS difference (p=0.176). Significant decrease in PFS was observed among those with advanced nodal N disease (median PFS in N0 and N+ was 10 and 5 months, respectively), non-responders (p=0.012), NLR (p=0.026) and those with an epithelial pathology (p=0.062). MVA demonstrated that advanced (N) status (p=0.015), being a non-responder (p<0.001), NLR (p=0.015) and smoking (p=0.07) adversely affected the prognosis. The only predictor of response was absence of metastasis (M0; p=0.04). CONCLUSIONS: In addition to previously recognized factors, like nodal status, response, smoking and NLR, better median survival was evident in our patients with a good PS. Early detection before development of metastasis warrants greater focus to allow better responses to be obtained. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5697462/ /pubmed/28843224 http://dx.doi.org/10.22034/APJCP.2017.18.8.2073 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Rahouma, Mohamed
Aziz, Hala
Ghaly, Galal
Kamel, Mohamed
Loai, Iman
Mohamed, Abdelrahman
Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
title Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
title_full Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
title_fullStr Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
title_full_unstemmed Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
title_short Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
title_sort survival in good performance malignant pleural mesothelioma patients; prognostic factors and predictors of response
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697462/
https://www.ncbi.nlm.nih.gov/pubmed/28843224
http://dx.doi.org/10.22034/APJCP.2017.18.8.2073
work_keys_str_mv AT rahoumamohamed survivalingoodperformancemalignantpleuralmesotheliomapatientsprognosticfactorsandpredictorsofresponse
AT azizhala survivalingoodperformancemalignantpleuralmesotheliomapatientsprognosticfactorsandpredictorsofresponse
AT ghalygalal survivalingoodperformancemalignantpleuralmesotheliomapatientsprognosticfactorsandpredictorsofresponse
AT kamelmohamed survivalingoodperformancemalignantpleuralmesotheliomapatientsprognosticfactorsandpredictorsofresponse
AT loaiiman survivalingoodperformancemalignantpleuralmesotheliomapatientsprognosticfactorsandpredictorsofresponse
AT mohamedabdelrahman survivalingoodperformancemalignantpleuralmesotheliomapatientsprognosticfactorsandpredictorsofresponse